Table 5.
Treatment responses among different inhalation therapies in CAT<10 group*
| Total | LAMA | LABA + LAMA | LABA + ICS | LABA + LAMA + ICS | P-value | |
|---|---|---|---|---|---|---|
|
Total number of participants
|
509 |
145 (28.5) |
70 (13.8) |
118 (23.2) |
176 (34.5) |
|
|
Exacerbations, MD (IQR)
|
0 (0–1) |
0 (0–1) |
0 (0–1) |
0 (0–1) |
0 (0–1) |
0.694 |
|
Exacerbations
|
|
|
|
|
|
0.486 |
| Yes |
187 (37.0) |
54 (37.8) |
28 (40.0) |
36 (31.0) |
69 (39.2) |
|
| No |
318 (63.0) |
89 (62.2) |
42 (60.0) |
80 (69.0) |
107 (60.8) |
|
|
Frequent exacerbations
|
|
|
|
|
|
0.987 |
| Yes |
81 (16.0) |
23 (16.1) |
12 (17.1) |
19 (16.4) |
27 (15.3) |
|
| No |
424 (84.0) |
120 (83.9) |
58 (82.9) |
97 (83.6) |
149 (84.7) |
|
|
Hospitalisations, MD (IQR)
|
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–1) |
0.286 |
|
Hospitalisations
|
|
|
|
|
|
0.310 |
| Yes |
113 (22.4) |
32 (22.4) |
17 (24.3) |
19 (16.4) |
45 (25.6) |
|
| No |
392 (77.6) |
111 (77.6) |
53 (75.7) |
97 (83.6) |
131 (74.4) |
|
|
All-cause mortality
|
|
|
|
|
|
0.267 |
| Yes |
4 (0.8) |
2 (1.4) |
0 (0.0) |
2 (1.7) |
0 (0.0) |
|
| No |
505 (99.2) |
143 (98.6) |
70 (100.0) |
116 (98.3) |
176 (100.0) |
|
|
Prescription outcomes
|
|
|
|
|
|
0.042 |
| Adjust treatment |
131 (25.7) |
49 (33.8) |
12 (17.1) |
28 (23.7) |
42 (23.9) |
|
| Continuous using | 378 (74.3) | 96 (66.2) | 58 (82.9) | 90 (76.3) | 134 (76.1) |
CAT – COPD assessment test, COPD – chronic obstructive pulmonary disease, ICS – inhaled corticosteroid, IQR – interquartile range, LABA – long-acting β2-agonist, LAMA – long-acting muscarinic antagonist, MD – median
*Presented as n (%) unless specified otherwise.